DLL3 and small cell lung carcinoma: The DLL3 ligand has been found to be highly expressed on the surface of SCLC cells and other high-grade neuroendocrine tumors and is becoming one of the most interesting targets of experimental therapies in SCLC with antibody–drug conjugates (ADCs), T-cell engager (TCE) molecules, and chimeric antigen receptor (CAR) [16].